Business Context and Reporting Period
Company: Protalix Biotherapeutics, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: January 4, 2011
Context: The filing discloses a regulatory and business development event under Regulation FD. The Company, a biopharmaceutical firm developing plant cell-expressed therapeutics, announced an invitation to present at a U.S. government industry day.
Key Financial Metrics
This filing is a current report regarding a specific event and does not contain financial statements. Consequently, the filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes
There are no financial material changes reported in this document. The material event is the invitation for Protalix to deliver an oral presentation on its lead candidate, PRX-105 (pegylated recombinant human acetylcholinesterase), at the Biomedical Advanced Research and Development Authority (BARDA) Industry Day.
Outlook, Commentary, and Risks
- Management Commentary: The presentation opportunity highlights the Company's engagement with the U.S. Department of Health and Human Services (HHS) regarding PRX-105 for therapeutic, prophylactic, biodefense, and pesticide treatment indications.
- Event Details: The presentation is scheduled for the HHS 5th Annual Public Health Emergency Medical Countermeasures Enterprise (PHEMCE) Stakeholders Workshop, held January 10–12, 2011, in Washington, D.C.
- Legal Disclaimer: The information in Item 7.01 is furnished, not "filed," under the Exchange Act and is not subject to Section 18 liabilities or incorporation by reference.
Investor Verification Checklist
- Verify the content and outcome of the oral presentation delivered at the BARDA Industry Day on January 10–12, 2011.
- Review the attached press release (Exhibit 99.1) for specific details on the biodefense and pesticide treatment programs.
- Monitor subsequent filings for any formal agreements or funding announcements resulting from the BARDA engagement.
- Check the Company's most recent 10-K or 10-Q for current financial status, as this 8-K contains no financial data.